Trial Profile
Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms OTILIA
- Sponsors Roche
- 07 Oct 2019 Status changed from active, no longer recruiting to completed.
- 11 Jul 2019 Planned End Date changed from 31 May 2019 to 30 Aug 2019.
- 11 Jul 2019 Planned primary completion date changed from 31 May 2019 to 30 Aug 2019.